banda transcan 2 2016ul

Title: Dual epigenetic targeting and immunotherapy to fight against cancer

Project Coordinator:
Felipe PROSPER (Spain) Clinica Universidad de Navarra, Pamplona, Navarra

Project Partners:
Karine BRECKPOT (Belgium) Vrije Universiteit Brussel (VUB), Laboratory of Molecular and Cellular Therapy, Laarbeeklaan, Brussels
Anna MONDINO (Italy) San Raffaele Scientific Institute, Division of Immunology, Transplantation and Infectious Diseases, Milan

Project Abstract:
Background/rationale: Epigenetic modifications are implicated in a variety of diseases including cancer. Thus, its modulation by using inhibitors of DNA methyltransferases (DNMT) or histone deacetylases have been developed and proved efficacious against cancer.
Recent evidence further suggests that these drugs have immunomodulatory properties and synergize with immunotherapy, representing another major breakthrough in cancer therapy. We developed novel compounds that simultaneously inhibit the activity of the histone methyltransferase G9a and DNMT1, showing a potent in vitro and in vivo activity against a wide range of cancers. These inhibitors also promote a pro-inflammatory signature, which might favor anti-tumor immunity.
Hypothesis: Combination of the newly defined epigenetic drugs with immunotherapeutic strategies represents a novel targeted chemo-immunotherapy approach with synergistic effects against cancer.
1) To study the molecular events underlying the anti-tumor and immunomodulatory activities of the newly defined G9a/DNMT1 dual inhibitor (CM272) in vitro and in vivo in comparison with approved hypomethylating agents.
2) To develop a novel combinatorial strategy with state-of-the art immunotherapies leading to a first-in-man clinical study.
Methods: Antitumor effect of CM272 will be tested in murine tumor models, alone or combined with vaccines, checkpoint inhibiting antibodies or adoptive T cell therapy. Immune cell subsets (effector T cells, Treg cells, and antigen presenting cells) will be studied over the course of treatment and tumor debulking on sorted populations by gene expression analysis, flow cytometry and functional assays.
Expected results and potential impact: Preclinical data will help elucidate anti-tumor and immunomodulatory effects of the newly designed dual epigenetic drug and define novel combinatorial strategies suitable for clinical application. Efficacy and safety will be determined to design a first-in-man-clinical study.

(Project funded under JTC 2015)


 TRANSCAN-3 news:
twitter logoinkedin social media logo
 The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download



The TRANSCAN-3 newsletters are published at:

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter

All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 15 guests and no members online